Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Resmed Inc (RMD)

Resmed Inc (RMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,146,006
  • Shares Outstanding, K 144,617
  • Annual Sales, $ 2,607 M
  • Annual Income, $ 404,590 K
  • 60-Month Beta 0.48
  • Price/Sales 9.76
  • Price/Cash Flow 37.34
  • Price/Book 11.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 1.04
  • Number of Estimates 4
  • High Estimate 1.08
  • Low Estimate 1.02
  • Prior Year 0.89
  • Growth Rate Est. (year over year) +16.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
158.16 +9.94%
on 01/31/20
177.99 -2.31%
on 02/19/20
+11.94 (+7.37%)
since 01/21/20
3-Month
144.56 +20.28%
on 11/22/19
177.99 -2.31%
on 02/19/20
+27.54 (+18.82%)
since 11/21/19
52-Week
96.81 +79.61%
on 04/18/19
177.99 -2.31%
on 02/19/20
+73.78 (+73.71%)
since 02/21/19

Most Recent Stories

More News
Zacks.com featured highlights include: Microsoft, Ruth???s Hospitality, ResMed, Ross Stores and Maxim Integrated Products

Zacks.com featured highlights include: Microsoft, Ruth???s Hospitality, ResMed, Ross Stores and Maxim Integrated Products

MSFT : 178.59 (-3.16%)
RUTH : 22.37 (-6.13%)
ROST : 123.24 (-0.46%)
RMD : 173.88 (-1.20%)
MXIM : 61.17 (-2.02%)
Integra (IART) Q4 Earnings Surpass Estimates, Margins Up

Integra's (IART) fourth-quarter 2019 results reflect strong segmental performances.

SYK : 224.30 (-0.08%)
IART : 59.27 (-2.05%)
RMD : 173.88 (-1.20%)
STE : 167.95 (-0.20%)
Globus Medical (GMED) Lags Q4 Earnings, Beats on Revenues

Globus Medical (GMED) registers impressive growth within U.S. Spine on record recruiting of competitive representatives in Q4.

SYK : 224.30 (-0.08%)
RMD : 173.88 (-1.20%)
STE : 167.95 (-0.20%)
GMED : 55.35 (-1.95%)
NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q4

NuVasive's (NUVA) Biologics business returns to growth in the fourth quarter of 2019.

SYK : 224.30 (-0.08%)
RMD : 173.88 (-1.20%)
STE : 167.95 (-0.20%)
NUVA : 75.16 (-4.82%)
20.3% Return Seen to Date on SmarTrend Resmed Inc Call (RMD)

SmarTrend identified an Uptrend for Resmed Inc (NYSE:RMD) on October 25th, 2019 at $144.33. In approximately 4 months, Resmed Inc has returned 20.27% as of today's recent price of $173.59.

RMD : 173.88 (-1.20%)
Add These 5 GARP Stocks to Your Portfolio for Maximum Returns

Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.

MSFT : 178.59 (-3.16%)
RUTH : 22.37 (-6.13%)
ROST : 123.24 (-0.46%)
RMD : 173.88 (-1.20%)
MXIM : 61.17 (-2.02%)
Bruker (BRKR) Stock Rises on Strong Preliminary Q4 Show

Bruker's (BRKR) revenue growth is expected to beat expectations for the fourth quarter and 2019.

SYK : 224.30 (-0.08%)
RMD : 173.88 (-1.20%)
STE : 167.95 (-0.20%)
BRKR : 49.58 (-0.52%)
Henry Schein Stock Hits New 52-Week High: What's Driving It?

Henry Schein (HSIC) is optimistic about maintaining growth momentum on several recent developments.

RMD : 173.88 (-1.20%)
Chemed (CHE) Q4 Earnings & Revenues Beat Estimates, Margins Up

Chemed's (CHE) fourth-quarter 2019 results reflect strong segmental performances.

SYK : 224.30 (-0.08%)
RMD : 173.88 (-1.20%)
STE : 167.95 (-0.20%)
CHE : 485.56 (-0.35%)
Tandem Diabetes Hits New 52-Week High: What's Driving It?

Tandem Diabetes (TNDM) is optimistic about maintaining growth momentum on several recent developments.

MDT : 113.28 (-0.51%)
RMD : 173.88 (-1.20%)
HRC : 106.26 (-0.84%)
TNDM : 88.00 (-2.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade RMD with:

Business Summary

ResMed Inc. is a world-leading connected health company with cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions....

See More

Key Turning Points

2nd Resistance Point 176.53
1st Resistance Point 175.21
Last Price 173.88
1st Support Level 173.05
2nd Support Level 172.21

See More

52-Week High 177.99
Last Price 173.88
Fibonacci 61.8% 146.98
Fibonacci 50% 137.40
Fibonacci 38.2% 127.82
52-Week Low 96.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar